EVMN — Evommune, Inc.

—
NYSE · Health Care · Pharmaceuticals · CIK 2044725 ·
Last close
$7.02
Market Cap
$290.28M
52W High
$33.20
52W Low
$4.94
ADV30
920,359
Next earnings
2026-11-16
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is headquartered in Palo Alto, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -33,326,000 -30,877,000 278,298,000 47,570,000 26,930,000
Jun 2026 0 — -34,895,000 -32,246,000 301,947,000 60,034,000 24,361,000
Mar 2026 0 — -23,954,000 -21,674,000 322,455,000 48,318,000 17,900,000
Dec 2025 0 — -29,716,000 -28,273,000 224,946,000 44,063,000 19,380,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-74,153,000
Investing CF
$-200,872,000
Financing CF
$274,217,000
CapEx
$-370,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.37
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-275,009,000
Inventory
—
Receivables
—
ST Investments
$140,759,000
EBIT TTM
$-101,893,000
Pretax Income TTM
$-94,668,000
Interest Exp TTM
—
Analysts
9

Yahoo Snapshot (yfinance, live)

Total Revenue
$0
EBITDA
$-120,125,000
Free Cash Flow
$-49,564,500
Enterprise Value
$155,053,424
Total Cash
$168,638,000
Total Debt
$8,192,000
Shares Out
41,349,860
Trailing EPS
$-3.83
Book Value
$6.91
ROE
-69.5%
ROA
-42.0%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 2y)

Revenues vs Net Income (last 2y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 13,000,000 -81,071,000 -68,870,000 224,946,000 19,380,000 205,566,000 -76,441,000
Dec 2024 — — — — — — —

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
$301,947,000
Forward EPS
$-3.47

Max Pain — expiry 2027-02-19 (volume-derived — Yahoo OI feed degraded)

max pain strike: $10.00 · spot: $6.88 · call volume: 31 · put volume: 25
Expected Move to 2027-02-19: ±$3.85 (55.96%) — implied range $3.03 – $10.73 · ATM straddle on $7.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
EBS Emergent BioSolutions Inc. $288.44M $5.61 —
GALT GALECTIN THERAPEUTICS INC $293.47M $2.91 —
MPLT MapLight Therapeutics, Inc. $286.78M $6.57 —
FULC Fulcrum Therapeutics, Inc. $286.43M $3.75 —
VCRE Vicore Pharma Holding AB $285.02M $10.12 —

News headlines (Yahoo Finance, 1h cache)

Evommune to Present at Upcoming Investor Conferences
2026-11-09 13:05 · Yahoo
Evommune Licenses Experimental Arthritis Drug, Raises $30 Million to Fund Development
2026-11-07 04:14 · Yahoo
Evommune signs $1.1bn licence deal with Hinova for EVO570
2026-11-05 11:36 · Yahoo
Evommune Announces Webcast Discussing EVO570 and Its Expanding Immunology Portfolio Today at 8:30 a.m. ET
2026-11-05 11:30 · Yahoo
Evommune Announces $30 Million Private Placement
2026-11-04 22:10 · Yahoo
Evommune Enters into Agreement to In-License EVO570, a Potential Best-in-Class Oral VAV1 Molecular Glue Degrader, from Hinova Pharmaceuticals
2026-11-04 22:02 · Yahoo
Migraine Market is Expected to Expand at 6% Growth Rate by 2036, Owing to the Development of Novel Mechanisms beyond CGRP, including PACAP-targeted Therapies, TRPA1 Antagonists, and Next-generation Ne
2026-10-19 17:00 · Yahoo
Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress
2026-10-01 12:00 · Yahoo
Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress
2026-09-23 20:05 · Yahoo
Evommune (EVMN) Drops EVO756 for Eczema. Can EVO301 Carry the Pipeline?
2026-09-16 19:55 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.